<?xml version="1.0" encoding="UTF-8"?>
<p id="p0370">Analyses of the cellular phosphoproteome, sometimes accompanied by phosphopeptide enrichment, have become standard to determine kinase activity (
 <xref rid="bb0990" ref-type="bibr">Lea and Simeonov, 2011</xref>, 
 <xref rid="bb1220" ref-type="bibr">Meyer et al., 2017</xref>, 
 <xref rid="bb1760" ref-type="bibr">Vyse et al., 2017</xref>). These assays can be used to assess the impact of inhibitors on the overall phosphoproteome in mammalian cells. Although these methods provide complex information about the overall array of kinases and phosphatases in the cell (
 <xref rid="bb1315" ref-type="bibr">Olsen et al., 2006</xref>), they are not applicable to screening inhibitors of a single viral kinase. For these purposes, 
 <italic>in vitro</italic> assays with recombinant kinases have been developed [for review see (
 <xref rid="bb1130" ref-type="bibr">Ma et al., 2008</xref>)], including some HTS fluorescence methods (
 <xref rid="bb1855" ref-type="bibr">Zegzouti et al., 2009</xref>) that can replace radioactive techniques using [Î³
 <sup>32</sup>P]ATP (
 <xref rid="bb1520" ref-type="bibr">Sanghera et al., 2009</xref>). Mass spectrometric analysis also can be used to identify 
 <italic>in vitro</italic> kinase inhibitors. For these analyses, synthetic peptides, proteins, or phosphatase- and heat-treated tissue samples (to dephosphorylate the proteins and inactivate all enzymes, respectively) are subjected to kinase treatment in the presence of inhibitors (
 <xref rid="bb0760" ref-type="bibr">Huang et al., 2007</xref>, 
 <xref rid="bb1220" ref-type="bibr">Meyer et al., 2017</xref>, 
 <xref rid="bb1820" ref-type="bibr">Xue et al., 2012</xref>).
</p>
